Athira Pharma Inc (ATHA) Stock Price, Quote & News

Company Profile

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed...

Industry: Biotechnology

Sector: Healthcare

Phone: 425 620 8501

Website: www.athira.com

Address:

18706 North Creek Parkway, Suite 104, Bothell, United States

SebNo1234 Jan. 7 at 2:42 PM

$ATHA

0 · Reply

Stonky_Mcprofitface Jan. 2 at 3:25 PM

$ATHA Spread is pretty wild but it seems to be tamed

0 · Reply

Stonky_Mcprofitface Dec. 30 at 8:42 PM

$ATHA This will go back to $4 where it started its improbable, unexplained, preposterous run.

0 · Reply

TrueWinner786 Dec. 30 at 4:59 PM

$ATHA I am keeping my eyes on $HYOR as well. This company will huge just check out the news for last 12 months...will be uplisted to OTCQB by next month. Delivered everything they said since the Reverse Merger. NASDAQ listing will be here very soon by another R/M.

0 · Reply

SebNo1234 Dec. 30 at 7:12 AM

$ATHA

0 · Reply

EyesWide Dec. 30 at 12:59 AM

$ATHA This ticker is so confused! Tipsy, possibly…Not sure which way is up or down 😂

0 · Reply

JL_TradeZ Dec. 28 at 5:11 PM

Monday Main Watchlist 29/12 $SOPA holding near highs after a big volume day. Small float and clean structure. Needs volume through 2.00 for continuation. $ATHA still holding up after the licensing news. If volume comes back and it clears 7.60–7.70, it can move again. $INDP tight coil around 2.50–2.60. Low float and buyers defending support. Break over 2.70–2.80 can start to go $RPGL consolidating near highs with volatility still there. Holding high 0.47s keeps it in play. $FTEL small float with volume and headlines still in play. Holding 0.88–0.90 is key for continuation

1 · Reply

IBOTTheDipAndTheDipWon Dec. 27 at 2:21 PM

$ATHA Caution warranted here.

0 · Reply

Stonky_Mcprofitface Dec. 26 at 8:02 PM

$ATHA They are gonna sneak in another offering here. Beware.

1 · Reply

Stonky_Mcprofitface Dec. 26 at 6:19 PM

$ATHA is being supported one share at a time on the Lii. Rug pull coming. Zero retail volume or momentum on the Cochran Retail Momentum indicator (11 minute snap).

0 · Reply

Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition?

Dec 18, 2025, 1:47 PM EST - 20 days ago

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Dec 18, 2025, 1:09 PM EST - 20 days ago

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Dec 18, 2025, 7:02 AM EST - 20 days ago

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Sep 11, 2025, 9:00 AM EDT - 4 months ago

Athira Pharma Announces Reverse Stock Split

May 13, 2025, 11:00 AM EDT - 8 months ago

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

May 9, 2025, 4:05 PM EDT - 8 months ago

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Feb 27, 2025, 4:05 PM EST - 11 months ago

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Jan 7, 2025, 5:15 PM EST - 1 year ago

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Dec 6, 2024, 5:30 PM EST - 1 year ago

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Nov 7, 2024, 4:05 PM EST - 1 year ago

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Sep 17, 2024, 11:59 AM EDT - 1 year ago

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Sep 17, 2024, 9:00 AM EDT - 1 year ago

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Sep 4, 2024, 8:48 AM EDT - 1 year ago

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Sep 3, 2024, 4:13 PM EDT - 1 year ago

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Jul 31, 2024, 8:05 AM EDT - 1 year ago

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

May 29, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming June Conferences

May 17, 2024, 5:00 PM EDT - 1 year ago

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 15, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 2, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming May Conferences

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Mar 8, 2024, 7:00 AM EST - 1 year ago

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Feb 22, 2024, 4:05 PM EST - 2 years ago

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Feb 8, 2024, 4:02 PM EST - 2 years ago

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Jan 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Jan 3, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Dec 12, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Nov 29, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Nov 15, 2023, 8:15 AM EST - 2 years ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Nov 8, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

Oct 5, 2023, 4:30 PM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Sep 19, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Jul 17, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Jul 6, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

May 22, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 8, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in Upcoming May Investor Conferences

Apr 25, 2023, 4:01 PM EDT - 2 years ago

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 11, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Mar 28, 2023, 1:00 AM EDT - 3 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Mar 23, 2023, 4:05 PM EDT - 3 years ago

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Mar 6, 2023, 7:00 AM EST - 3 years ago

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Feb 1, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Jan 31, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Jan 5, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Provides 2023 Pipeline Outlook

SebNo1234 Jan. 7 at 2:42 PM

$ATHA

0 · Reply

Stonky_Mcprofitface Jan. 2 at 3:25 PM

$ATHA Spread is pretty wild but it seems to be tamed

0 · Reply

Stonky_Mcprofitface Dec. 30 at 8:42 PM

$ATHA This will go back to $4 where it started its improbable, unexplained, preposterous run.

0 · Reply

TrueWinner786 Dec. 30 at 4:59 PM

0 · Reply

SebNo1234 Dec. 30 at 7:12 AM

$ATHA

0 · Reply

EyesWide Dec. 30 at 12:59 AM

$ATHA This ticker is so confused! Tipsy, possibly…Not sure which way is up or down 😂

0 · Reply

JL_TradeZ Dec. 28 at 5:11 PM

1 · Reply

IBOTTheDipAndTheDipWon Dec. 27 at 2:21 PM

$ATHA Caution warranted here.

0 · Reply

Stonky_Mcprofitface Dec. 26 at 8:02 PM

$ATHA They are gonna sneak in another offering here. Beware.

1 · Reply

Stonky_Mcprofitface Dec. 26 at 6:19 PM

$ATHA is being supported one share at a time on the Lii. Rug pull coming. Zero retail volume or momentum on the Cochran Retail Momentum indicator (11 minute snap).

0 · Reply

Stonky_Mcprofitface Dec. 26 at 12:12 PM

$ATHA Buying opportunity

0 · Reply

IBOTTheDipAndTheDipWon Dec. 26 at 12:00 PM

$ATHA Let it fall, let it fall, let it fall.

0 · Reply

Changinc Dec. 25 at 3:31 PM

$ATHA This is a scam company with no adequate pipelines and lied about their data caused their last CEO to resigned. No way such a press as some top tier institutional investors pooled in 100s millions to buy then a phase 3 drug? Lol,,,lol 😆 🤣,,if those institutional investors really existed they would've bought it themselves.

0 · Reply

Stonky_Mcprofitface Dec. 24 at 12:31 PM

$ATHA Rug pull coming over next three sessions.

0 · Reply

masonjoel99 Dec. 24 at 3:00 AM

$ATHA $AVGO $MDLN $MU $ORCL I joined one yesterday…all they did was try to upsell. I,cancelled.

0 · Reply

TrueWinner786 Dec. 23 at 5:07 PM

$SNSE another great stock is $ATHA huge potential after the last exclusive licensing news.

0 · Reply

IBOTTheDipAndTheDipWon Dec. 23 at 4:58 PM

$ATHA All I want for Christmas is a big dump.

0 · Reply

Stock__Hunter Dec. 23 at 3:12 PM

$ATHA she likes to sleep in the mornings

0 · Reply

Stonky_Mcprofitface Dec. 23 at 3:22 AM

$ATHA This company has solid fundamentals on which to build a portfolio. The list is endless. The company has a name. It operates on planet Earth. It’s on LinkedIn and its management team manages.

1 · Reply

Changinc Dec. 22 at 9:59 PM

$ATHA This company operates like a scam. First the previous CEO fudge and fake data got caught and then resigned. Struggling with nonexistent pipelines or if they even exist a lab. Who are thos top tier investors that poured in 100s of millions for them to buy this mystery phase3 drug? Does people actually buy it?

2 · Reply

SebNo1234 Dec. 22 at 7:48 PM

$ATHA

0 · Reply

Stonky_Mcprofitface Dec. 22 at 6:38 PM

$ATHA Now is the time to calmly and prudently,but without delay, head for the exits.

0 · Reply

Market Cap	27.45M
Revenue (ttm)	0.00
Net Income (ttm)	-96.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	86,100
Avg Vol	1,295,570
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	68%
Beta	2.79
Analysts	Hold
Price Target	$4.00